HOME > Articles >

Korean J Gastroenterol  <  Volume 74(4); 2019 <  Articles

Korean J Gastroenterol 2019; 74(4): 199-204  https://doi.org/10.4166/kjg.2019.74.4.199
Inhibitory Effects of β-caryophyllene on Helicobacter pylori Infection: A Randomized Double-blind, Placebo-controlled Study
Hyun Ik Shim1, Dong Jin Song1, Cheol Min Shin1, Hyuk Yoon1, Young Soo Park1, Nayoung Kim1,2 and Dong Ho Lee1,2
Department of Internal Medicine, Seoul National University Bundang Hospital1, Seongnam; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine2, Seoul, Korea
Correspondence to: Dong Ho Lee, Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea. Tel: +82-31-787-7008, Fax: +82-31-787-4051, E-mail: dhljohn@yahoo.com, ORCID: https://orcid.org/0000-0002-6376-410X
Received: May 13, 2019; Revised: June 7, 2019; Accepted: July 31, 2019; Published online: October 25, 2019.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background/Aims: Helicobacter pylori (H. pylori) infections, which cause a variety of gastrointestinal symptoms, are common in South Korea. Recent reports have shown a decline in the H. pylori eradication rates. β-caryophyllene is a natural bicyclic sesquiterpene that occurs in a wide range of plant species, such as cloves, basil, and cinnamon. β-caryophyllene has been reported to have anti-inflammatory and anti-bacterial effects. This study investigated the inhibitory effects of β-caryophyllene on H. pylori and its potential role as an alternative gastrointestinal drug.
Methods: This 8-week, randomized double-blind, placebo-controlled trial categorized subjects into a β-caryophyllene group (33 patients who received 126 mg/day of β-caryophyllene) and a placebo group (33 patients who received a placebo preparation). The inflammation level of H. pylori infiltration and the eradication rates were evaluated endoscopically and with the urea breath test (UBT) in both groups before and after administering the medication. The serum cytokine levels (tumor necrosis factor-α, and interleukin [IL]-1β and IL-6) were compared in both groups before and after administering the medication.
Results: Complete eradication was not observed in either group. Moreover, there was no significant change in the UBT and updated Sydney score. On the other hand, the β-caryophyllene group showed significant improvement in nausea (p=0.025) and epigastric pain (p=0.018), as well as a decrease in the serum IL-1β levels (p=0.038).
Conclusions: β-caryophyllene improves dyspepsia symptoms and can be considered a useful supplementary treatment for gastrointestinal disease.
Keywords: Helicobacter pylori; β-caryophyllene; Therapeutics; Dyspepsia


This Article


Author ORCID Information

Stats or Metrics
  • View: 52
  • Download: 62

Services
Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • thomson reuters
  • pubmedcentral
  • koreamed
  • crossref
  • crossref
  • synepse
  • kofst
  • DOAJ
  • ORCID